Chris Seibert, MBA, CEO

 Mr. Seibert has over 20 years of Life Science business experience, most recently co-leading the exit of Titan Medical to Medtronic, Intuitive Surgical, and Auris Health (Johnson & Johnson). He has been involved with four start-ups at various stages having led sales, marketing, business development, and product development and having raised over $250M in start-up capital for these companies. He has held executive roles in two publicly traded life science companies (Stereotaxis and Titan Medical).  He is experienced with leading small and large teams to achieve commercial/corporate objectives ahead of schedule. Mr. Seibert previously served for 7.5 years as a Captain in the United States Air Force and currently serves on the Athens City Council, having served as President twice.  He is a member of numerous non-profit boards and organizations. 

Experienced business and scientific leader with over 20 years of biotech experience. Mr. Singhal’s research career began at the University of Alabama at Birmingham (UAB) studying sialylated beta integrin mediated cancer metastasis. From there, Mr. Singhal, performed mechanistic studies on the genetic disease erythropoietic protoporphyria in the UAB Liver Center. At the University of Alabama in Huntsville (UAH), Mr. Singhal studied extremophile microorganisms and their enzymes for industrial use. He went on to found the Protein Services and Drug Discover divisions at iXpressGenes Inc.. Mr. Singhal led the acquisition of iXpressGenes’ Drug Discovery Division by CFD Research Corporation, which included the Extremophile Derived Natural Product (EDeN) drug discovery platform. While at CFD Research, Mr. Singhal has been the PI on 11 SBIR drug discovery projects. He has led teams which are developing new classes of antibacterials, antivirals and anticancer compounds. He is the lead inventor on the NIH-funded eczema patch program that Kalm Therapeutics is based on.

Dr. Viegas brings over 25 years of experience in pharmaceutical drug development.  He has led discovery and development activities for both synthetically and biologically derived therapeutic agents in the areas of oncology, neurology, influenza, psoriasis, and wound care.  Prior to joining Kalm, he served as the Chief Operating Officer at Serina Therapeutics, where he was responsible for the early development efforts in chemistry, manufacturing and controls (CMC) and in the evaluation of preclinical safety and efficacy.  Dr. Viegas worked in different progressive management roles at Nektar Therapeutics where he was a co-inventor of nalexogol (Movantik®) and etirinotecan pegol (Onzealdä), at BioCryst Pharmaceuticals where he was part of the early development team for peramivir (Rapivabä), and at MDV Technologies where he invented and developed FloGelä for the treatment of burns, bruises and abrasions. Movantik® was licensed and sold to Astra Zeneca for total deal value of about $1.0 billion.  Onzeald™ was licensed to Daiichi Sankyo Europe GmbH for $60 million and royalties of 20% of net sales. Flogelä wound dressing was acquired by Alliance Pharmaceuticals of San Diego, CA. 

Dr. Viegas received his B.S. in Chemistry and Pharmacy from Bangalore University, and his M.S. and Ph.D. in Pharmaceutical Sciences from the University of Mississippi.  He has over 50 patents issued, of which 10 are in the area of skin health treatment.  He also serves on the scientific advisory committee of the National Institutes for Health (NIH-NIDA), on the publication committee of the American College of Clinical Pharmacology (ACCP) and is a member of numerous non-profit and charity organizations.

Dr. Maeda-Chubachi, a board-certified dermatologist,  brings over 20 years of experience in topical drug development, clinical affairs, and strategic partnerships. 

 She brings extensive experience in dermatology drug development with Pfizer, Eli Lilly, and GSK. While at GSK, Dr. Maeda-Chubachi was responsible for leading the Phase II clinical trial of eczema/psoriasis topical cream, Vtama. The clinical trial design and results led to the acquisition of Vtama by Dermavant for $250M. Most recently, she led clinical development and medical affairs in Pelthos Therapeutics (formerly known as Novan) as the Chief Medical Officer and brought an approval of Zelsuvmi for treatment of molluscum contagiosum. She has an extensive network of key industry personnel and physicians in the field of dermatology.